Humana Inc. $HUM Stake Trimmed by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC lessened its holdings in Humana Inc. (NYSE:HUM) by 7.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,000 shares of the insurance provider’s stock after selling 2,000 shares during the period. Humana makes up approximately 1.9% of Sivik Global Healthcare LLC’s portfolio, making the stock its 8th largest position. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,504,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Blue Trust Inc. grew its stake in Humana by 3.6% during the 2nd quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock worth $334,000 after purchasing an additional 48 shares in the last quarter. Private Wealth Management Group LLC boosted its stake in shares of Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after buying an additional 48 shares during the period. Atlas Brown Inc. grew its position in shares of Humana by 0.9% during the second quarter. Atlas Brown Inc. now owns 6,369 shares of the insurance provider’s stock worth $1,557,000 after buying an additional 54 shares in the last quarter. Ossiam grew its position in shares of Humana by 1.6% during the second quarter. Ossiam now owns 4,375 shares of the insurance provider’s stock worth $1,070,000 after buying an additional 71 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Humana by 15.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 518 shares of the insurance provider’s stock worth $135,000 after buying an additional 71 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 1.4%

HUM opened at $279.68 on Wednesday. The stock has a market capitalization of $33.64 billion, a P/E ratio of 26.21, a price-to-earnings-growth ratio of 2.25 and a beta of 0.45. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. Humana Inc. has a one year low of $206.87 and a one year high of $315.35. The business’s 50-day simple moving average is $254.85 and its 200-day simple moving average is $261.82.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. Humana had a return on equity of 12.86% and a net margin of 1.02%.The firm had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. During the same quarter last year, the business posted $4.16 EPS. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, December 26th. Humana’s payout ratio is presently 33.18%.

Wall Street Analysts Forecast Growth

Several research firms have commented on HUM. KeyCorp reiterated a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Humana in a research note on Friday, October 3rd. Jefferies Financial Group upgraded Humana from a “hold” rating to a “buy” rating and raised their price target for the company from $253.00 to $313.00 in a research note on Friday, December 5th. Wells Fargo & Company cut Humana from an “overweight” rating to a “cautious” rating in a research report on Wednesday. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $344.00 price objective on shares of Humana in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $292.05.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.